Chondrial Therapeutics

6 articles about Chondrial Therapeutics

• Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

  5/29/2020

  - Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chief Financial Officer appointed BALA CYNWYD, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ann

• 

  Clinical Catch-Up: December 16-20

  12/23/2019

  Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.

• Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

  12/18/2019

  Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

• Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s AtaxiaCTI-1601 granted Rare Pediatric Disease Designation and Fast Track Designation by U.S. FDA

  12/18/2019

  Chondrial Therapeutics announced that the first patients have been dosed in a Phase 1 clinical trial to evaluate the safety and tolerability of single ascending doses of CTI-1601.

• Chondrial Therapeutics Announces FDA Orphan Drug Designation For CTI-1601, A Novel Investigational Technology For The Treatment Of Friedreich's Ataxia

  8/3/2017

• Chondrial Therapeutics Secures Up To $22.6 Million In Series A Financing And Licenses Novel Technology For The Treatment Of Friedreich's Ataxia

  2/6/2017